Lineage Cell Therapeutics (LCTX) Gross Margin (2011 - 2026)

Lineage Cell Therapeutics' Gross Margin history runs 16 years deep, the most recent figure standing at 100.0% for Q1 2026.

• In Q1 2026, Gross Margin rose 240.0% year-over-year to 100.0%; the TTM figure through Mar 2026 stood at 99.26% (up 210.0% YoY), while the FY2025 annual figure was 99.0%, up 251.0% from the prior year.
• Gross Margin for Q1 2026 stood at 100.0%, up from 99.0% in the prior quarter.
• The five-year high for Gross Margin was 100.0% in Q1 2026, with the low at 86.44% in Q3 2023.
• The 5-year median for Gross Margin is 96.06% (2023), against an average of 95.46%.
• The sharpest annual moves came in 2022 and 2023: Gross Margin surged 9275 bps in 2022, then tumbled 693 bps in 2023.
• Lineage Cell Therapeutics' Gross Margin stood at 94.67% in 2022, then declined by 7 bps to 87.74% in 2023, then climbed by 8 bps to 94.63% in 2024, then grew by 5 bps to 99.0% in 2025, then advanced by 1 bps to 100.0% in 2026.
• Business Quant data shows LCTX's Gross Margin at 100.0% in Q1 2026, 99.0% in Q4 2025, and 99.86% in Q3 2025.